BioCentury | Jun 10, 2013
Clinical News

Ensituximab: Phase I/IIa data

...reported (see BioCentury, April 22). Last September, Precision Biologics purchased the assets, including ensituximab, of Neogenix Oncology Inc....
BioCentury | Apr 22, 2013
Clinical News

Ensituximab: Phase I data

...meeting in Chicago in June. Last September, Precision Biologics purchased the assets, including ensituximab, of Neogenix Oncology Inc....
BioCentury | Apr 25, 2011
Clinical News

Neogenix Oncology preclinical data

...CEACAM6 . Data were presented at the American Association for Cancer Research meeting in Orlando. Neogenix Oncology Inc....
BioCentury | Jan 24, 2011
Clinical News

NPC-1C ELISA diagnostic data

...NPC-1C chimeric mAb is in Phase I testing to treat advanced colorectal and pancreatic cancer. Neogenix Oncology Inc....
BioCentury | Nov 8, 2010
Clinical News

NPC-1C regulatory update

...from immunogenic glycoprotein is in Phase I testing to treat advanced pancreatic and colorectal cancer. Neogenix Oncology Inc....
BioCentury | Apr 5, 2010
Company News

Neogenix Oncology management update

Neogenix Oncology Inc. , Great Neck, N.Y. Business: Cancer Promoted: Philip Arlen to CEO, while remaining president, CMO and a director; he replaces Myron Arlen, who will become chairman WIR Staff cancer...
BioCentury | Feb 8, 2010
Clinical News

NPC-1C: Phase I started

...I trial in 24 patients to evaluate 1, 2, 4 and 8 mg/kg IV NPC-1C. Neogenix Oncology Inc....
BioCentury | Jan 26, 2009
Company News

Neogenix Oncology, International Bio Immune Systems deal

...quarter. Neogenix said the transfer of assets is part of International Bio Immune's planned dissolution. Neogenix Oncology Inc....
BioCentury | Sep 15, 2008
Company News

Neogenix Oncology management update

Neogenix Oncology Inc. , Great Neck, N.Y. Business: Cancer Hired: Philip Arlen as president, CMO and a director, formerly director of the clinical research group at the Laboratory of Tumor Immunology and Biology at the National...
BioCentury | Jul 2, 2007
Company News

Goodwin Biotechnology Inc., Neogenix Oncology deal

...pancreatic cancer in 1H08. Financial terms were not disclosed. Goodwin Biotechnology Inc. , Plantation, Fla. Neogenix Oncology Inc....
Items per page:
1 - 10 of 10
BioCentury | Jun 10, 2013
Clinical News

Ensituximab: Phase I/IIa data

...reported (see BioCentury, April 22). Last September, Precision Biologics purchased the assets, including ensituximab, of Neogenix Oncology Inc....
BioCentury | Apr 22, 2013
Clinical News

Ensituximab: Phase I data

...meeting in Chicago in June. Last September, Precision Biologics purchased the assets, including ensituximab, of Neogenix Oncology Inc....
BioCentury | Apr 25, 2011
Clinical News

Neogenix Oncology preclinical data

...CEACAM6 . Data were presented at the American Association for Cancer Research meeting in Orlando. Neogenix Oncology Inc....
BioCentury | Jan 24, 2011
Clinical News

NPC-1C ELISA diagnostic data

...NPC-1C chimeric mAb is in Phase I testing to treat advanced colorectal and pancreatic cancer. Neogenix Oncology Inc....
BioCentury | Nov 8, 2010
Clinical News

NPC-1C regulatory update

...from immunogenic glycoprotein is in Phase I testing to treat advanced pancreatic and colorectal cancer. Neogenix Oncology Inc....
BioCentury | Apr 5, 2010
Company News

Neogenix Oncology management update

Neogenix Oncology Inc. , Great Neck, N.Y. Business: Cancer Promoted: Philip Arlen to CEO, while remaining president, CMO and a director; he replaces Myron Arlen, who will become chairman WIR Staff cancer...
BioCentury | Feb 8, 2010
Clinical News

NPC-1C: Phase I started

...I trial in 24 patients to evaluate 1, 2, 4 and 8 mg/kg IV NPC-1C. Neogenix Oncology Inc....
BioCentury | Jan 26, 2009
Company News

Neogenix Oncology, International Bio Immune Systems deal

...quarter. Neogenix said the transfer of assets is part of International Bio Immune's planned dissolution. Neogenix Oncology Inc....
BioCentury | Sep 15, 2008
Company News

Neogenix Oncology management update

Neogenix Oncology Inc. , Great Neck, N.Y. Business: Cancer Hired: Philip Arlen as president, CMO and a director, formerly director of the clinical research group at the Laboratory of Tumor Immunology and Biology at the National...
BioCentury | Jul 2, 2007
Company News

Goodwin Biotechnology Inc., Neogenix Oncology deal

...pancreatic cancer in 1H08. Financial terms were not disclosed. Goodwin Biotechnology Inc. , Plantation, Fla. Neogenix Oncology Inc....
Items per page:
1 - 10 of 10